Elevation Oncology Alpha and Beta Analysis
| ELEVDelisted Stock | USD 0.37 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Elevation Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Elevation Oncology over a specified time horizon. Remember, high Elevation Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Elevation Oncology's market risk premium analysis include:
Beta (0.14) | Alpha 0.31 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Elevation |
Elevation Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Elevation Oncology market risk premium is the additional return an investor will receive from holding Elevation Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Elevation Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Elevation Oncology's performance over market.| α | 0.31 | β | -0.14 |
Elevation Oncology Fundamentals Vs Peers
Comparing Elevation Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Elevation Oncology's direct or indirect competition across all of the common fundamentals between Elevation Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Elevation Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Elevation Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Elevation Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Elevation Oncology to competition |
| Fundamentals | Elevation Oncology | Peer Average |
| Return On Equity | -0.78 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Current Valuation | (27.78 M) | 16.62 B |
| Shares Outstanding | 59.25 M | 571.82 M |
| Shares Owned By Insiders | 0.35 % | 10.09 % |
| Shares Owned By Institutions | 59.72 % | 39.21 % |
| Number Of Shares Shorted | 2.08 M | 4.71 M |
Elevation Oncology Opportunities
Elevation Oncology Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 6250 shares by Joseph Ferra of Elevation Oncology subject to Rule 16b-3 | 05/15/2025 |
2 | Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for 0.36 in Cash per Share Plus a Contingent Value Right | 06/09/2025 |
3 | This McDonalds Analyst Turns Bearish Here Are Top 4 Downgrades For Tuesday | 06/10/2025 |
4 | Q2 EPS Estimate for Elevation Oncology Reduced by Analyst | 06/11/2025 |
5 | Elevation Oncology Cut to Hold at William Blair | 06/12/2025 |
6 | Disposition of 12560 shares by Joseph Ferra of Elevation Oncology subject to Rule 16b-3 | 06/16/2025 |
About Elevation Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Elevation or other delisted stocks. Alpha measures the amount that position in Elevation Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Elevation Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Elevation Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Elevation Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Elevation Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Elevation Oncology. Please utilize our Beneish M Score to check the likelihood of Elevation Oncology's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Elevation Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Elevation Stock
If you are still planning to invest in Elevation Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elevation Oncology's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |